Back to top

Research Daily

Wednesday, April 24, 2019

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Celgene (CELG), Schlumberger (SLB) and Becton, Dickinson (BDX). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Celgene’s shares have gained +25.4% in the past six months, outperforming the Zacks Biomedical and Genetics industry's decline of -2.6%. The Zacks analyst thinks Celgene’s key growth driver, Revlimid, continues to drive revenues. Robust performance of psoriasis drug, Otezla, is also boosting performance.

Investors are focusing on the company’s merger agreement with Bristol-Myers Squibb Company. Per the terms, Celgene shareholders will receive 1.0 share of Bristol-Myers and $50.00 in cash for each share held. Meanwhile, Celgene is also working on the label expansion of drugs like Pomalyst/Imnovid, Abraxane and Otezla, among others.

The company is focused on the next cycle of innovation with five late-stage candidates — ozanimod, fedratinib, luspatercept, liso-cel and bb2121 — all of which are expected to be launched by the end of 2020. However, the company’s dependence on Revlimid for growth is a concern. Also, pipeline setbacks are a deterrent.

(You can read the full research report on Celgene here >>>).

Shares of Schlumberger have underperformed the Zacks Oil and Gas - Field Services industry over the past year, losing -33.6% vs. -19.4%. The Zacks analyst stresses that Schlumberger is the largest oilfield services player in the world with presence in every energy market.

The company expects improvement in oilfield services in international markets where the count of drilling rigs and final investment decisions (FID) for clients’ projects are on the rise. Schlumberger’s first-quarter 2019 earnings matched expectations, courtesy of contributions from Integrated Drilling Services (IDS) projects in Saudi Arabia, India and Mexico.

However, the bottom line declined year over year owing to lower contributions from directional drilling in the land market of North America. Decline in OneStim revenues from the continent’s onshore regions added to concerns. Moreover, conservative spending by North America’s explorers and producers is likely to hurt demand for Schlumberger’s oilfield services.

(You can read the full research report on Schlumberger here >>>).

Becton, Dickinson’s shares have underperformed the Zacks Dental Supplies industry year to date, gaining +1.2% vs. +8.2%. The Zacks analyst likes the solid performance by the core BD Medical and Life Sciences units. Domestic and international revenues increased year over year in recent times.

Management is optimistic about the C.R. Bard buyout which has consistently proven to be accretive. Notably, a series of product launches and regulatory approvals in recent times continue to boost the stock. The company has kept its fiscal 2019 guidance intact. However, contraction in gross and operating margins in recent times is worrisome for Becton, Dickinson.

Customer ordering patterns are also expected to negatively impact fiscal second-quarter results. Management expects unfavorable foreign currency to remain headwinds in fiscal 2019. Stiff price competition in the MedTech space adds to the woes.

(You can read the full research report on Becton, Dickinson here >>>).

Other noteworthy reports we are featuring today include Intuitive Surgical (ISRG), Twitter (TWTR) and PPG Industries (PPG).

Will you retire a millionaire?

One out of every six people retires a multimillionaire. Get smart tips you can do today to become one of them in a new Special Report, “7 Things You Can Do Now to Retire a Multimillionaire.”

Click to get it free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Featured Reports

New Upgrades

New Downgrades

High SG&A Expenses Weigh on Genuine Parts (GPC)

Per the Zacks analyst, rising costs of payroll, freight & delivery, IT, and cybersecurity are adding to Genuine Parts' SG&A expenses. This is, in turn, is putting pressure on its profit margins.